(Q53304624)

English

Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance.

scientific article published on 24 August 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance. (English)

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Murugan Kalimutho

1

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

Antonella Minutolo

2

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

Sandro Grelli

3

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

Amanda Formosa

4

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

Giulia Sancesario

5

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

Alessandra Valentini

6

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

Giorgio Federici

7

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

Sergio Bernardini

8

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

publication date

24 August 2010

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

67

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

6

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

1299-1312

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

https://scigraph.springernature.com/pub.10.1007/s00280-010-1428-4

0 references

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

In vitro studies on the mechanisms of oxaliplatin resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Particular aspects of platinum compounds used at present in cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Cancer. p53, guardian of the genome

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

New-generation platinum drugs in the treatment of cisplatin-resistant cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Preclinical antitumor activity of the oral platinum analog satraplatin

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Repression of cyclin B1 expression after treatment with adriamycin, but not cisplatin in human lung cancer A549 cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

p53 enters the microRNA world

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1428-4

21 January 2018

Identifiers

10.1007/S00280-010-1428-4

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/20734047

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53304624&oldid=1512266928"